Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Navin Fluorine International - Cashing-in new opportunities still far way - ICICI Securities

Posted On: 2020-10-30 08:23:01 (Time Zone: Arizona, USA)

Navin Fluorine International's (NFIL) Q2FY21 EBITDA grew 38% YoY on strong growth in CRAMS revenue (110% YoY) and lower cost inflation. It saw CRAMS annual run rate jump to Rs2.6bn from Rs2bn earlier on tailwinds from strong Europe and US orderbooks. It is working on improving efficiency of cGMP-3 plant, which should improve asset turns. NFIL remains excited on rising opportunities from its entry into high performance and adjacent products, and now into Hexofluoro. However, its promised capex announcement in specialty chemicals is long pending. We see FY22E growth dependent on CRAMS as the specialty segment is now at optimal capacity utilisation. We have slightly increased our estimates, rolled over valuations to Sep'22 and assigned a higher P/E multiple at 30x (from 26x) on rising opportunities. Thus, our fair value for NFIL rises to Rs2,086 (from Rs1,575). Maintain REDUCE.

- CRAMS drives revenue growth. Standalone revenues rose 16.6% YoY to Rs3bn driven by CRAMS revenue rise of 110% to Rs1bn, and specialty chemicals revenue growth of 8.5%. Ref-gas and inorganic fluoride revenues were down 17% and 5.8% YoY to Rs580mn and Rs490mn respectively. CRAMS revenues were aided by a strong order from one customer as indicated in Q4FY20 earnings call, and a few other orders bunching up. cGMP-3 plant saw utilisation of 80% and run-rate guidance has been increased to Rs1.3bn for half year from earlier Rs1bn in CRAMS sans quarterly volatility.

- Gross margin hurt from pricing pressures in legacy business. Gross margin dipped 280bps QoQ despite higher revenue contribution from CRAMS. This was due to pricing pressures in ref-gas and inorganic fluorides; however, the extent of margin dip cannot be entirely explained from pricing, in our view. EBITDA margin came at a strong 30% (up 500bps QoQ) as 80% of incremental gross profit flowed into EBITDA. EBITDA grew 38% YoY to Rs935mn and net profit was 45% YoY higher at Rs673mn.

- Hexofluoro adds to rising opportunities. NFIL is exploring more opportunities in high performance products (HPP) in fluorine chemistry after signing a multi-year contract. It has added another platform from Piramal JV - Hexofluoro where the products find use in pharmaceuticals and electric vehicles. Further, the company is also working on new fluorine use cases (only player in eastern hemisphere) for batteries, etc.

- Other highlights. 1) NFIL is working on improving its processes and yields, and is reducing batch cycle to extract more out of the cGMP-3 plant. It also plans minor debottlenecking, which would add to capacity. Assessment for adding cGMP-4 will be made only in FY22/FY23; 2) in specialty chemicals, it has many molecules in various stages of development from R&D, piloting and commercialisation. A few of them will require dedicated facilities while others can be manufactured in multi-purpose plants. Management would announce firm capex plans by end-FY21; 4) NFIL has agreed to sell its 49% equity in Piramal JV to the JV partner at Rs650mn vs investment of Rs320mn. It will also part with 11 acres of land out 85 acres for Rs79mn.

Shares of Navin Fluorine International Limited was last trading in BSE at Rs.2241.35 as compared to the previous close of Rs. 2278. The total number of shares traded during the day was 19389 in over 3126 trades.

The stock hit an intraday high of Rs. 2339 and intraday low of 2227.35. The net turnover during the day was Rs. 44269806.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Kajaria Ceramics (Initiating Coverage) - Galloping ahead - HDFC Securities

UltraTech Q3 FY21 - YES Securities

HDFC Life Q3 FY21 - YES Securities

SBI Life - Q3 FY21 - YES Securities

Aavas Financiers Q3 FY21 - Conference Call Takeaways - YES Securities

Birla Corp Q3 FY21 - YES Securities

ADD on Reliance Industries - Sailed through the tough times! - HDFC Securities

Grasim Industries - Aspiring for strong no.2 position in paints - ICICI Securities

Kewal Kiran Clothing - Better execution with flat EBITDA YoY - ICICI Securities

Mphasis - DXC will continue to be key in the near term - ICICI Securities

HDFC Securities: Indian Chemical Sector (Sector Update) - Steering well through the pandemic!

UltraTech Cement - Earnings upgrade continues; ripe for rerating - ICICI Securities

Multi Commodity Exchange of India - Lower turnover impacted operating performance - Q3FY21 - ICICI Securities

SBI Life Insurance Company - Strong performance, attractive valuations (<2 FY23 P/EV) - ICICI Securities

Biocon Limited - Slow recovery in biosimilars - ICICI Securities

HDFC Life Insurance Company - Not only - but also - about protection - ICICI Securities

DCB Bank - Gradually approaching normalcy - ICICI Securities

Aurobindo Pharma - Approval for 3 products under PLI Scheme - ICICI Securities

Yes Bank - Aggravating asset quality fears outweigh operating performance turnaround - ICICI Securities

JSW Steel - Peak margins expected in Q4FY21 - ICICI Securities

Aavas Financiers - Quality intact; premium to sustain - ICICI Securities

Supreme Industries - Q3FY21 First Cut - ICICI Direct

Polycab India Ltd - Q3FY21 First Cut - ICICI Direct

DCB Bank - Q3FY21 First Cut - ICICI Direct

Q3FY21 Result update - Symphony Ltd. - ICICI Direct

Ultratech Cement - Q3FY21 First Cut - ICICI Direct

Oberoi Realty - Q3FY21 First Cut - ICICI Direct

HDFC Life Insurance - Q3FY21 First Cut - ICICI Direct

SRF Limited - Chemical biz's good performance may continue - ICICI Securities

Multi Commodity Exchange of India - Lower turnover impacted operating performance - ICICI Securities

Q3FY21 Company update - Zensar Technologies - ICICI Direct

JSW Steel - Q3FY21 First Cut - ICICI Direct

Q3FY21 Result update - Biocon Ltd - ICICI Direct

Symphony Ltd - Q3FY21 First Cut - ICICI Direct

Crompton Greaves Consumer Electricals - Q3FY21 First Cut - ICICI Direct

Q3FY21 Result update - Bajaj Finserv - ICICI Direct

Q3FY21 Result update - Bajaj Auto - ICICI Direct

Quant Pick - Hero MotoCorp - ICICI Direct

Company update - Cyient Ltd - Q3FY21 - ICICI Direct

Covid Recovery Pulse - Auto retail taper off in new year 2021 - ICICI Direct

Q3FY21 Result update - Asian Paints - ICICI Direct

Company update - Mphasis Ltd - Q3FY21 - ICICI Direct

SBI Life Insurance - Q3FY21 First Cut - ICICI Direct

Q3FY21 Result update - Syngene International - ICICI Direct

Stove Kraft Ltd (SKL) - IPO - Weak Financial Track Record - Reliance Securities

Maintain BUY on Bandhan Bank - Prudently cushioning for potential event risk - HDFC Securities

Maintain SELL on Asian Paints - Bolt out of the blue - HDFC Securities

Maintain ADD on Cyient - Gradual acceleration - HDFC Securities

Maintain ADD on Havells India - Beat across the board; justifying rich valuation - HDFC Securities

Maintain SELL on Shoppers Stop - Still not out of the woods! - HDFC Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020